Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Obesity, Pre-diabetes
Interventions: Empagliflozin 25 MG; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy, Smokers, Asthma
Interventions: Whole Body Periodic Acceleration (WBPA), Sham WBPA; Device
Lead sponsor: University of Miami; Other
Eligibility: 20 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Blood Pressure, Endothelial Dysfunction
Interventions: Empagliflozin (EMPA), Placebo; Drug · Other
Lead sponsor: Kanokwan Bunsawat; Other
Eligibility: 45 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions: UCMSCs, BMMSCs, Placebo; Biological · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 21 Years to 95 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: Aerobic Exercise Training; Other
Lead sponsor: Baltimore VA Medical Center; Federal
Eligibility: 50 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Cancer
Interventions: Lucitanib; Drug
Lead sponsor: Teresa Helsten, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Non-small Cell Lung Cancer
Interventions: BNT326, Pumitamig; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more

Conditions: Hepatocellular Carcinoma
Interventions: Zanzalintinib, Durvalumab, Tremelimumab; Drug
Lead sponsor: Anwaar Saeed; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Houston, Texas • San Antonio, Texas

Conditions: Cardiovascular Disease
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions: Pazopanib Hydrochloride, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Pharmacological Study, Laboratory Biomarker Analysis; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Preeclampsia Postpartum
Interventions: Losartan Potassium, Placebo; Drug
Lead sponsor: Anna Stanhewicz, PhD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions: raltegravir, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: End Stage Renal Disease, Cardiovascular Disease, Inflammation
Interventions: Pomegranate juice, Pomegranate fruit extract; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Posttraumatic Stress Disorder, Insomnia
Interventions: Personalized sleep intervention; Behavioral
Lead sponsor: Howard University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 2
States / cities: Bethesda, Maryland • Fairfax, Virginia

Conditions: Obesity, Endothelial Dysfunction
Interventions: Exercise; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Type 1 Diabetes
Interventions: Ramipril, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 50 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Gainesville, Florida • Chicago, Illinois • Maywood, Illinois

Conditions: Scleroderma, Pulmonary Hypertension
Interventions: No intervention; Other
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Atherosclerosis
Interventions: salsalate, placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liver Cancer
Interventions: Sunitinib Malate; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Macular Degeneration
Interventions: Pazopanib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more

Conditions: Vascular, Endothelial, Endothelial Dysfunction, Endothelix
Interventions: Vendys II Device; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 6 Years to 26 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
Interventions: sparsentan, No sparsentan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: Lucentis (Ranibizumab); Drug
Lead sponsor: University of Miami; Other
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

Effect of Whole Body Periodic Acceleration on Airway Endothelial Function

Neurovascular Effects of Empagliflozin

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function

Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery

Losartan for Improved Vascular Endothelial Function After Preeclampsia

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

Pomegranate and Hemodialysis Pilot Trial

Stress, Sleep and Cardiovascular Risk

Blood Collection for Research Related to Certain Diseases Involving Blood Vessels

Microvascular Dysfunction in Obesity

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension

Inflammation and Vascular Function in Atherosclerosis

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

An Extension to Study MD7108240

Feasibility of Digital Thermal Monitoring to Assess Endothelium-Dependent Vasodilation in Patients Undergoing Hematopoietic Cell Transplantation (HCT)

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)